Forschungshinweis Dieses Produkt ist ausschlielich fr die Laborforschung bestimmt
Conservative combination protocol (if attempting) Rationale for conservative approach: No safety data available Both peptides slow gastric emptying significantly Risk of severe GI complications Start low, go slow principle Tirzepatide component: Follow standard FDA-approved titration Weeks 1-4: 2.5mg weekly Weeks 5-8: 5mg weekly Weeks 9-12: 7.5mg weekly Weeks 13-16: 10mg weekly Week 17+: 12.5mg weekly (or stay at 10mg) Some reach 15mg weekly (maximum) Cagrilintide component (reduced from standard): Start AFTER tirzepatide stabilized at therapeutic dose (week 13+) Week 13-16: 0.6mg weekly (lower than standard) Week 17-20: 1.2mg weekly Week 21-24: 1.8mg weekly (may be maximum tolerable) Consider 2.4mg only if tolerating perfectly Conservative dosing comparison: Why sequential is safer: Tirzepatide establishes baseline first Can attribute new side effects to cagrilintide Easier to manage one variable at a time Option to stop cagrilintide if intolerable Less overwhelming than both simultaneously Expected benefits: 18-25% total weight loss (conservative estimate) Potentially superior to tirzepatide alone (15-22%) But incremental benefit may be modest (3-5% additional) Use SeekPeptides to plan sequential peptide additions safely
However, because retatrutide has the additional glucagon receptor component, starting at a lower-than-expected dose and titrating up remains the safest approach
What differs is the second (and third) pathway each adds: CagriSema adds amylin, tirzepatide adds GIP, retatrutide adds both GIP and glucagon
Combining with other peptides like BPC-157 and TB-500 for healing, MOTS-c for metabolic support, or growth hormone secretagogues lacks formal study but is practiced in some protocols
Secondary endpoints in trials include reductions in waist circumference , visceral fat mass, appetite scores, and daily caloric intake
